Open Access

Fukuyama-type congenital muscular dystrophy and defective glycosylation of α-dystroglycan

  • Fumiaki Saito1 and
  • Kiichiro Matsumura1
Skeletal Muscle20111:22

DOI: 10.1186/2044-5040-1-22

Received: 15 February 2011

Accepted: 1 June 2011

Published: 1 June 2011

Abstract

Fukuyama-type congenital muscular dystrophy (FCMD) is a severe form of muscular dystrophy accompanied by abnormalities in the eye and brain. The incidence of FCMD is particularly high in the Japanese population. Mutations in the fukutin gene have been identified in patients with FCMD. Fukutin is predicted to be a Golgi apparatus resident protein and to be involved in the post-translational modification of cell-surface proteins. Recently, progress has been made in our understanding of the molecular mechanisms by which the mutation of fukutin leads to the phenotype of FCMD. Loss of function of fukutin results in defective glycosylation of α-dystroglycan, a central component of the dystrophin-glycoprotein complex, leading to disruption of the linkage between basal lamina and cytoskeleton. This disruption is implicated in the pathogenesis of both the MD and brain anomalies in FCMD. Furthermore, genetic analyses have revealed that the spectrum of the FCMD phenotype is much wider than originally thought. In this review, we summarize the diverging clinical phenotype of FCMD and its molecular pathomechanisms.

Clinical features of FCMD and mutation of fukutin

Congenital muscular dystrophies (CMDs) are a group of clinically and genetically heterogeneous muscular disorders. Fukuyama-type congenital muscular dystrophy (FCMD) is a unique disorder, which until recently had been reported almost exclusively in the Japanese population. FCMD is one of the most common autosomal recessive disorders and is the second most common form of muscular dystrophy in Japan after Duchenne MD. The incidence of FCMD is particularly high in the Japanese population (2.89 per 100,000 births) [1], and the carrier rate in Japan is estimated to be one in 90. FCMD was first described in 1960 by Fukuyama et al[2].

FCMD is characterized by severe MD accompanied by brain malformation and ocular abnormalities. Patients have generalized muscle weakness and hypotonia from early infancy. Motor development is delayed, and the maximum level of motor function, which is achieved between 2 and 8 years of age, is unassisted sitting, sliding on the buttocks, or sometimes standing with support. Thereafter, motor function declines severely because of progressive muscle weakness and joint contracture. Pseudohypertrophy of the calves and tongue are often seen, as well as a dilated cardiomyopathy that becomes symptomatic in the second decade of life [2].

Development of intellectual, cognitive and communicative functions are also delayed. Most patients have mental retardation, and about half of patients have epilepsy [3]. The most common brain anomaly in FCMD is cobblestone lissencephaly, which includes micropolygyria, fibroglial proliferation of the leptomeninges, and focal interhemispheric fusion. The neuronal lamination of the normal six-layered cortex is lost. Hydrocephalus, cerebellar cysts and hypoplasia of the corticospinal tract, pons and cerebellar vermis are commonly present [2, 4]. Ocular abnormalities such as retinal dysplasia, retinal detachment, optic nerve atrophy, myopia and strabismus are often seen on ophthalmological examination [5, 6].

In 1993, Toda et al. initially mapped the FCMD locus to chromosome 9q31-33 [7]. After localizing the gene to a region of <100 kb containing the marker D9S2107, they finally identified a mutation of the fukutin gene in 1998 [8]. A retrotransposal insertion of 3 kb of novel tandemly repeated sequence into the 3' untranslated region of this gene constitutes the founder mutation. It seems to derive from a single ancestor, and accounts for >80% of the FCMD locus in the Japanese population. This insertion causes a significant reduction in the level of corresponding mRNA by rendering the mRNA unstable, which causes the FCMD phenotype due to loss of function [8]. In addition, several non-founder mutations, including a nonsense or missense point mutation, small deletion, small insertion and L1 insertion were identified [9].

The fukutin gene spans >100 kb of genomic DNA, and is composed of 10 exons. It encodes a protein of 461 amino acids with a predicted molecular weight of 53.7 kDa [8]. Native fukutin protein has not been detected to date in skeletal muscle, probably because of its low expression level; however, overexpressed fukutin localizes to the Golgi apparatus in some cell lines [10]. Hydrophobicity plots and secondary structure analysis predict that fukutin is an enzyme that modifies cell-surface glycoproteins or glycolipids, most probably through the attachment of phosphoryl-sugar moieties [11]. However, the actual enzymatic activity of fukutin has not yet been identified. Instead, another possibility regarding its function has been proposed. Fukutin colocalizes and forms a complex with protein O-mannose β-1, 2-N-acetylglucosaminyltransferase (POMGnT1), a glycosyltransferase involved in the synthesis of O-mannosyl glycan attached to α-dystroglycan (see below). In addition, POMGnT1 activity is decreased in fukutin-deficient mouse tissues. Taken together, these results indicate that fukutin may function as a modulator of POMGnT1 [12].

Until the identification of the mutations in the fukutin gene, it was hypothesized that FCMD might be a disorder unique to the Japanese population. However, since 2003, an increasing number of fukutin mutations have been reported outside of Japan. Most cases are compound heterozygotes of point mutations, small deletions or duplications [13]. Recently, the founder mutation (the 3 kb retrotransposal insertion) was also identified in the non-Japanese East Asian population [14, 15]. In addition, the phenotype of the fukutin mutation has been found to have a much broader spectrum than originally thought. At one end, a condition that is more severe than typical FCMD and resembles Walker-Warburg syndrome (WWS) (see below), has also been found to be caused by mutations of fukutin [16], whereas at the milder end, there is a phenotype of limb-girdle MD that does not involve brain anomaly or mental retardation [16]. Interestingly, Murakami et al. reported patients with fukutin mutations presenting with a dilated cardiomyopathy with no or minimal MD nor mental retardation [17].

Structure and function of α-dystroglycan

The dystrophin-glycoprotein complex (DGC) is a multimeric protein complex located at the sarcolemma of muscle fibers. The DGC consists of the dystroglycan complex, sarcoglycan-sarcospan complex, syntrophin, neuronal nitric oxide synthase, dystrobrevin and dystrophin. The integrity of this complex is crucial for the normal function and viability of muscle cells. Dystroglycan is encoded by a single gene, Dag1, located on human chromosome 3p21 and cleaved into two proteins, α- and β-dystroglycan, by post-translational processing [18]. α-dystroglycan is a highly glycosylated, extracellular peripheral-membrane protein with a molecular weight of 156 kDa in skeletal muscle, and binds to several proteins of the extracellular matrix (ECM) including laminin, agrin and perlecan, and synaptic proteins such as neurexin and pikachurin [18, 19]. The transmembrane protein β-dystroglycan, with a molecular weight of 43 kDa, anchors α-dystroglycan to the extracellular surface of the plasma membrane. The cytoplasmic domain of β-dystroglycan interacts with dystrophin, a large cytoplasmic protein that binds to F-actin. Thus, dystroglycan plays a central role in the DGC to stabilize the plasma membrane by acting as an axis that links the ECM to the cytoskeleton.

α-dystroglycan is composed of distinct three domains: the N-terminal, mucin-like and C-terminal domains. The N-terminal domain is cleaved by the proprotein convertase, furin, and secreted outside cells [20, 21]. The mucin-like domain is highly glycosylated by O-linked oligosaccharides, and the sugar-chain moiety constitutes up to two-thirds of the molecule. Chiba et al. reported that O-mannosyl glycan (Siaα2-3Galβ1-4GlcNAcβ1-2Man), is attached to the serine or threonine residues on α-dystroglycan as a major sialylated O-linked oligosaccharide structure. This unique glycan is necessary for the binding with its ligands (α-dystroglycan) [22]. Recently, it was found that the mannose residue of the O-mannosyl glycan is modified by an ancient type of phosphoryl glycan, and that this modification is also necessary for binding to laminin [23].

Dystroglycan not only mechanically stabilizes the sarcolemma against contraction-stretch stress, but also plays a role in signal transduction. The β-dystroglycan cytoplasmic domain binds to growth factor receptor-bound protein 2 (Grb2), an adaptor protein involved in signal transduction and cytoskeletal organization [24]. Furthermore, in vitro experiments have shown that a tyrosine residue in the PPXY motif of the C terminus of β-dystroglycan is phosphorylated in an adhesion-dependent manner, and that this tyrosine phosphorylation abolishes the binding of dystrophin and its homolog, utrophin, to the PPXY motif [25]. This tyrosine phosphorylation of β-dystroglycan in turn recruits the SH2 domain-containing signaling proteins such as the c-Src, Fyn, c-Src tyrosine kinase (Csk), non-catalytic region of tyrosine kinase adaptor protein (NCK) and Src homology 2 domain-containing (SHC) proteins [26]. Recently, it was reported that the binding of laminin to α-dystroglycan causes signaling through the dystroglycan-syntrophin-Grb2-SOS1-Rac1-PAK1-JNK cascade which is initiated by Src family kinases, and also causes syntrophin tyrosine phosphorylation to begin signaling [27].

Dysfunction of α-dystroglycan in FCMD and related disorders

In 2001, Hayashi et al. reported that the immunoreactivity of the antibody against the sugar-chain moiety of α-dystroglycan is severely reduced in the skeletal muscle of patients with FCMD, suggesting defective glycosylation of α-dystroglycan [28]. Subsequently, Michele et al. showed, using an antibody against the core protein of α-dystroglycan, that in the skeletal muscle of patients with FCMD, α-dystroglycan is hypoglycosylated as a result of mutations in fukutin. Intriguingly, these authors also showed that the binding activity of α-dystroglycan for the ligands such as laminin, agrin or neurexin is severely reduced [29]. Furthermore, Yoshida-Moriguchi et al. recently reported that the postphosphoryl modification of the phosphorylated O-mannose is defective in the skeletal muscle of patients with FCMD [23]. These findings are consistent with previous studies reporting that the sugar-chain moiety of α-dystroglycan (O-mannosyl glycan in particular) is crucial for the interaction between α-dystroglycan and laminin interaction. Disruption of the linkage between α-dystroglycan and laminin is predicted to have profound effects on muscle-cell viability, because it causes destabilization of the sarcolemma against contraction-stretch stress, hampers signal transduction, and inhibits the assembly of ECM proteins (Figure 1).
Figure 1

The dysfunction of α-dystroglycan in Fukuyama-type congenital MD (FCMD). (A) The normal dystrophin-glycoprotein complex (DGC) in skeletal muscle. α-dystroglycan binds to laminin via the O-linked glycan chain moiety, including Siaα2-3Galβ1-4GlcNAcβ1-2Man and a phosphoryl glycan attached to the mannose. Details of the postphosphoryl glycan modification are still unknown. The N-terminal domain of α-dystroglycan is cleaved by furin and secreted. (B) The DGC in FCMD. The mutation in fukutin causes defects in postphosphoryl modification of the O-linked glycan, resulting in disruption of the linkage between α-dystroglycan and laminin, and leading to destabilization of the sarcolemma. The modification of O-linked mannose by Siaα2-3Galβ1-4GlcNAcβ remains to be elucidated in FCMD.

The same pathomechanisms underlie several types of MD other than FCMD. A homolog of fukutin, fukutin-related protein (FKRP), was cloned, and point mutations in the FKRP gene were identified in patients with congenital muscular dystrophy 1C (MDC1C) [30]. MDC1C, prevalent in white populations, is a severe form of CMD, occasionally associated with brain or ocular anomalies. A milder form of limb-girdle muscular dystrophy (LGMD) 2I is an allelic disorder to MDC1C. The enzymatic activity of FKRP has not yet been identified. Muscle-eye-brain (MEB) disease, found mainly in Finland, is typically characterized by severe brain and ocular abnormalities and CMD. Mutations of the POMGnT1 gene have been found in patients with MEB [31]. POMGnT1 catalyzes the GlcNAcβ1-2Man linkage in the O-mannosyl glycan of α-dystroglycan.

WWS is one of the most severe types of CMD, and is accompanied by marked brain malformation and structural eye abnormalities. Typically, the brain of patients with WWS is more severely affected than the brain of patients with FCMD or MEB. Mutations in protein O-mannosyltransferase (POMT)1 and POMT2 are present in patients with WWS. POMT1 and POMT2 form a complex, and are involved in the first step of O-mannosyl glycosylation in which mannose is attached to the serine or threonine residues of α-dystroglycan [32, 33]. MDC1D, another form of CMD, is a rare disorder characterized by severe MD accompanied by brain malformation. Mutations of the LARGE (like-glycosyltransferase) gene have been identified in patients with MDC1D. Interestingly, a recent paper reported that LARGE is involved in the phosphoryl glycosylation of O-mannnosyl glycan attached to α-dystroglycan [23]. In all the MDs described above, biochemical data have confirmed that dysfunction of α-dystroglycan underlies the pathogenesis, and therefore they are collectively called the α-dystroglycanopathies.

One of the prominent hallmarks of FCMD is the presence of brain anomalies, that is, of cobblestone lissencephaly [2, 4]. It is of particular importance to note that the glia limitans-basal lamina complex is frequently disrupted, and neuroglial tissues protrude through the cleft into the subarachnoid space in the brain of patients with FCMD [34]. This disruption of the glia limitans-basal lamina complex causes migration defects of neurons, and eventually results in further anomalies such as the disarray of cerebral cortical layering or the formation of the unique appearance of the micropolygyria. In the brain, fukutin is expressed by neurons and glial cells, and colocalizes with α-dystroglycan [35, 36]. The fukutin-deficient chimeric mouse, a model of FCMD, exhibits essentially the same brain anomalies as seen in patients with FCMD, with defective glycosylation of α-dystroglycan also present in the mouse brain [37]. Interestingly, the specific disruption of dystroglycan in mouse astrocyte or epiblast results in very similar neuropathological findings to those of FCMD [3840]. In these mice, the laminin-binding activity of α-dystroglycan is severely reduced in the brain. Taken together, these observations strongly support the idea that the functional defect in α-dystroglycan is central to the pathogenesis of brain malformation in FCMD (Figure 2).
Figure 2

The molecular pathomechanism leading to brain anomaly in Fukuyama-type congenital MD (FCMD). (A) On the normal cerebral surface, α-dystroglycan in the glia limitans binds to laminin in the basal lamina. (B) Glycosylation of α-dystroglycan is defective in FCMD, which causes disruption of the dystroglycan-laminin binding, leading to misassembly of laminin and disorganization of basal lamina. This facilitates the overmigration of neuronal cells through the fragmented basal lamina to the subarachnoid space, and results in disarray of cerebral cortical layering and malformation of gyri.

Conclusion

A broad spectrum of clinical presentations is now attributed to mutations in the fukutin gene. Recent progress in molecular genetics and biochemistry in this area has confirmed that defective post-translational modification of α-dystroglycan caused by the fukutin mutation underlies the pathogenesis of MD. The defective glycosylation results both in degeneration of the skeletal muscle and in migration defects of neurons in the brain through disruption of the α-dystroglycan-laminin linkage. Consequently, amelioration or upregulation of the dystroglycan function may be the most suitable molecular target for therapies for FCMD. The putative glycosyltransferase LARGE is now known to restore the defective dystroglycan function [41, 42], thus, it may be of benefit in the treatment of FCMD. Further experiments are necessary to shed further light on the pathomechanism of FCMD and to facilitate the development of a therapeutic strategy.

Declarations

Acknowledgements

We thank Miki Ikeda for her expert technical assistance. This work was supported by an Intramural Research Grant (20B-13, 22-1 and 23-5) for Neurological and Psychiatric Disorders of NCNP, Research on Psychiatric and Neurological Diseases and Mental Health H20-016 (Ministry of Health, Labor and Welfare); and a Grant-in Aid for Scientific Research (C), numbers 21591099 and 20591035, from MEXT (Ministry of Education, Culture, Sports, Science and Technology).

Authors’ Affiliations

(1)
Department of Neurology and Neuroscience, Teikyo University School of Medicine

References

  1. Osawa M, Sumida S, Suzuki N, Arai Y, Ikenaka H, Murasugi H, Shishikura K, Suzuki H, Saito K, Fukuyama Y: Fukuyama type congenital progressive muscular dystrophy. In Congenital Muscular Dystrophies. Edited by: Fukuyama Y, Osawa M, Saito K. Amsterdam: Elsevier; 1997:31-68.Google Scholar
  2. Fukuyama Y, Kawazura M, Haruna H: A peculiar form of congenital progressive muscular dystrophy: Report of fifteen cases. Paediatr Univ Tokyo 1960, 4: 5-8.Google Scholar
  3. Yoshioka M, Higuchi Y, Fujii T, Aiba H, Toda T: Seizure-genotype relationship in Fukuyama-type congenital muscular dystrophy. Brain Dev 2008, 30: 59-67. 10.1016/j.braindev.2007.05.012View ArticlePubMedGoogle Scholar
  4. Takada K, Nakamura H, Tanaka J: Cortical dysplasia in congenital muscular dystrophy with central nervous system involvement (Fukuyama type). J Neuropathol Exp Neurol 1984, 43: 395-407. 10.1097/00005072-198407000-00005View ArticlePubMedGoogle Scholar
  5. Tsutsumi A, Uchida Y, Osawa M, Fukuyama Y: Ocular findings in Fukuyama type congenital muscular dystrophy. Brain Dev 1989, 11: 413-419.View ArticlePubMedGoogle Scholar
  6. Hino N, Kobayashi M, Shibata N, Yamamoto T, Saito K, Osawa M: Clinicopathological study on eyes from cases of Fukuyama type congenital muscular dystrophy. Brain Dev 2001, 23: 97-107. 10.1016/S0387-7604(01)00189-9View ArticlePubMedGoogle Scholar
  7. Toda T, Segawa M, Nomura Y, Nonaka I, Masuda K, Ishihara T, Sakai M, Tomita I, Origuchi Y, Suzuki M: Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 1993, 5: 283-286. 10.1038/ng1193-283View ArticlePubMedGoogle Scholar
  8. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, Segawa M, Yoshioka M, Saito K, Osawa M, Hamano K, Sakakihara Y, Nonaka I, Nakagome Y, Kanazawa I, Nakamura Y, Tokunaga K, Toda T: An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394: 388-392. 10.1038/28653View ArticlePubMedGoogle Scholar
  9. Kondo-Iida E, Kobayashi K, Watanabe M, Sasaki J, Kumagai T, Koide H, Saito K, Osawa M, Nakamura Y, Toda T: Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum Mol Genet 1999, 8: 2303-2309. 10.1093/hmg/8.12.2303View ArticlePubMedGoogle Scholar
  10. Esapa CT, Benson MA, Schröder JE, Martin-Rendon E, Brockington M, Brown SC, Muntoni F, Kröger S, Blake DJ: Functional requirements for fukutin-related protein in the Golgi apparatus. Hum Mol Genet 2002, 11: 3319-3331. 10.1093/hmg/11.26.3319View ArticlePubMedGoogle Scholar
  11. Aravind L, Koonin EV: The fukutin protein family--predicted enzymes modifying cell-surface molecules. Curr Biol 1999, 9: R836-837. 10.1016/S0960-9822(00)80039-1View ArticlePubMedGoogle Scholar
  12. Xiong H, Kobayashi K, Tachikawa M, Manya H, Takeda S, Chiyonobu T, Fujikake N, Wang F, Nishimoto A, Morris GE, Nagai Y, Kanagawa M, Endo T, Toda T: Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of α-dystroglycan. Biochem Biophys Res Commun 2006, 350: 935-941. 10.1016/j.bbrc.2006.09.129View ArticlePubMedGoogle Scholar
  13. Yis U, Uyanik G, Heck PB, Smitka M, Nobel H, Ebinger F, Dirik E, Feng L, Kurul SH, Brocke K, Unalp A, Özer E, Cakmakci H, Sewry C, Cirak S, Muntoni F, Hehr U, Morris-Rosendahl DJ: Fukutin mutations in non-Japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-Walker-Warburg phenotype. Neuromuscul Disord 2011, 21: 20-30. 10.1016/j.nmd.2010.08.007View ArticlePubMedGoogle Scholar
  14. Xiong H, Wang S, Kobayashi K, Jiang Y, Wang J, Chang X, Yuan Y, Liu J, Toda T, Fukuyama Y, Wu X: Fukutin gene retrotransposal insertion in a non-Japanese Fukuyama congenital muscular dystrophy (FCMD) patient. Am J Med Genet A 2009, (149A):2403-2408.
  15. Lim BC, Ki CS, Kim JW, Cho A, Kim MJ, Hwang H, Kim KJ, Hwang YS, Park WY, Lim YJ, Kim IO, Lee JS, Chae JH: Fukutin mutations in congenital muscular dystrophies with defective glycosylation of dystroglycan in Korea. Neuromuscul Disord 2010, 20: 524-530. 10.1016/j.nmd.2010.06.005View ArticlePubMedGoogle Scholar
  16. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, Jimenez-Mallebrera C, Mercuri E, Manzur AY, Kinali M, Torelli S, Brown SC, Sewry CA, Bushby K, Topaloglu H, North K, Abbs S, Muntoni F: Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007, 130: 2725-2735. 10.1093/brain/awm212View ArticlePubMedGoogle Scholar
  17. Murakami T, Hayashi YK, Noguchi S, Ogawa M, Nonaka I, Tanabe Y, Ogino M, Takada F, Eriguchi M, Kotooka N, Campbell KP, Osawa M, Nishino I: Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006, 60: 597-602. 10.1002/ana.20973View ArticlePubMedGoogle Scholar
  18. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992, 355: 696-702. 10.1038/355696a0View ArticlePubMedGoogle Scholar
  19. Sato S, Omori Y, Katoh K, Kondo M, Kanagawa M, Miyata K, Funabiki K, Koyasu T, Kajimura N, Miyoshim T, Sawai H, Kobayashi K, Tani A, Toda T, Usukura J, Tano Y, Fujikado T, Furukawa T: Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci 2008, 11: 923-931. 10.1038/nn.2160View ArticlePubMedGoogle Scholar
  20. Kanagawa M, Saito F, Kunz S, Yoshida-Moriguchi T, Barresi R, Kobayashi YM, Muschler J, Dumanski JP, Michele DE, Oldstone MB, Campbell KP: Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 2004, 117: 953-964. 10.1016/j.cell.2004.06.003View ArticlePubMedGoogle Scholar
  21. Saito F, Saito-Arai Y, Nakamura A, Shimizu T, Matsumura K: Processing and secretion of the N-terminal domain of α-dystroglycan in cell culture media. FEBS Lett 2008, 582: 439-444. 10.1016/j.febslet.2008.01.006View ArticlePubMedGoogle Scholar
  22. Chiba A, Matsumura K, Yamada H, Inazu T, Shimizu T, Kusunoki S, Kanazawa I, Kobata A, Endo T: Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve α-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of α-dystroglycan with laminin. J Biol Chem 1997, 272: 2156-2162. 10.1074/jbc.272.4.2156View ArticlePubMedGoogle Scholar
  23. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, Madson M, Oldstone MB, Schachter H, Wells L, Campbell KP: O-mannosyl phosphorylation of α-dystroglycan is required for laminin binding. Science 2010, 327: 88-92. 10.1126/science.1180512PubMed CentralView ArticlePubMedGoogle Scholar
  24. Yang B, Jung D, Motto D, Meyer J, Koretzky G, Campbell KP: SH3 domain-mediated interaction of dystroglycan and Grb2. J Biol Chem 1995, 270: 11711-11714. 10.1074/jbc.270.20.11711View ArticlePubMedGoogle Scholar
  25. Ilsley JL, Sudol M, Winder SJ: The interaction of dystrophin with β-dystroglycan is regulated by tyrosine phosphorylation. Cell Signal 2001, 13: 625-632. 10.1016/S0898-6568(01)00188-7View ArticlePubMedGoogle Scholar
  26. Sotgia F, Lee H, Bedford MT, Petrucci T, Sudol M, Lisanti MP: Tyrosine phosphorylation of β-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins. Biochemistry 2001, 40: 14585-14592. 10.1021/bi011247rView ArticlePubMedGoogle Scholar
  27. Zhou Y, Jiang D, Thomason DB, Jarrett HW: Laminin-induced activation of Rac1 and JNKp46 is initiated by Src family kinases and mimics the effects of skeletal muscle contraction. Biochemistry 2007, 46: 14907-14916. 10.1021/bi701384kPubMed CentralView ArticlePubMedGoogle Scholar
  28. Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, Arahata K: Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001, 57: 115-121.View ArticlePubMedGoogle Scholar
  29. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP: Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418: 417-422. 10.1038/nature00837View ArticlePubMedGoogle Scholar
  30. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, Ponting CP, Estournet B, Romero NB, Mercuri E, Voit T, Sewry CA, Guicheney P, Muntoni F: Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan. Am J Hum Genet 2001, 69: 1198-1209. 10.1086/324412PubMed CentralView ArticlePubMedGoogle Scholar
  31. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, Inazu T, Mitsuhashi H, Takahashi S, Takeuchi M, Herrmann R, Straub V, Talim B, Voit T, Topaloglu H, Toda T, Endo T: Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001, 1: 717-724. 10.1016/S1534-5807(01)00070-3View ArticlePubMedGoogle Scholar
  32. Manya H, Chiba A, Yoshida A, Wang X, Chiba Y, Jigami Y, Margolis RU, Endo T: Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci USA 2004, 101: 500-505. 10.1073/pnas.0307228101PubMed CentralView ArticlePubMedGoogle Scholar
  33. Akasaka-Manya K, Manya H, Nakajima A, Kawakita M, Endo T: Physical and functional association of human protein O-mannosyltransferases 1 and 2. J Biol Chem 2006, 281: 19339-19345. 10.1074/jbc.M601091200View ArticlePubMedGoogle Scholar
  34. Saito Y, Murayama S, Kawai M, Nakano I: Breached cerebral glia limitans-basal lamina complex in Fukuyama-type congenital muscular dystrophy. Acta Neuropathol 1999, 98: 330-336. 10.1007/s004010051089View ArticlePubMedGoogle Scholar
  35. Sasaki J, Ishikawa K, Kobayashi K, Kondo-Iida E, Fukayama M, Mizusawa H, Takashima S, Sakakihara Y, Nakamura Y, Toda T: Neuronal expression of the fukutin gene. Hum Mol Genet 2000, 9: 3083-3090. 10.1093/hmg/9.20.3083View ArticlePubMedGoogle Scholar
  36. Ohtsuka-Tsurumi E, Saito Y, Yamamoto T, Voit T, Kobayashi M, Osawa M: Co-localization of fukutin and α-dystroglycan in the mouse central nervous system. Brain Res Dev Brain Res 2004, 152: 121-127.View ArticlePubMedGoogle Scholar
  37. Chiyonobu T, Sasaki J, Nagai Y, Takeda S, Funakoshi H, Nakamura T, Sugimoto T, Toda T: Effects of fukutin deficiency in the developing mouse brain. Neuromuscul Disord 2005, 15: 416-426. 10.1016/j.nmd.2005.03.009View ArticlePubMedGoogle Scholar
  38. Moore SA, Saito F, Chen J, Michele DE, Henry MD, Messing A, Cohn RD, Ross-Barta SE, Westra S, Williamson RA, Hoshi T, Campbell KP: Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 2002, 418: 422-425. 10.1038/nature00838View ArticlePubMedGoogle Scholar
  39. Satz JS, Barresi R, Durbeej M, Willer T, Turner A, Moore SA, Campbell KP: Brain and eye malformations resembling Walker-Warburg syndrome are recapitulated in mice by dystroglycan deletion in the epiblast. J Neurosci 2008, 28: 10567-10575. 10.1523/JNEUROSCI.2457-08.2008PubMed CentralView ArticlePubMedGoogle Scholar
  40. Satz JS, Ostendorf AP, Hou S, Turner A, Kusano H, Lee JC, Turk R, Nguyen H, Ross-Barta SE, Westra S, Hoshi T, Moore SA, Campbell KP: Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J Neurosci 2010, 30: 14560-14572. 10.1523/JNEUROSCI.3247-10.2010PubMed CentralView ArticlePubMedGoogle Scholar
  41. Barresi R, Michele DE, Kanagawa M, Harper HA, Dovico SA, Satz JS, Moore SA, Zhang W, Schachter H, Dumanski JP, Cohn RD, Nishino I, Campbell KP: LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 2004, 10: 696-703. 10.1038/nm1059View ArticlePubMedGoogle Scholar
  42. Kanagawa M, Nishimoto A, Chiyonobu T, Takeda S, Miyagoe-Suzuki Y, Wang F, Fujikake N, Taniguchi M, Lu Z, Tachikawa M, Nagai Y, Tashiro F, Miyazaki J, Tajima Y, Takeda S, Endo T, Kobayashi K, Campbell KP, Toda T: Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum Mol Genet 2009, 18: 621-631.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Saito and Matsumura; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.